Kadir Gultekin

Mr. Kadir Gultekin

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
YKYogesh Kumar
Yogesh Kumar
RCRex A. Cardan
Rex A. Cardan
HCHo-hsin Chang
Ho-hsin Chang
KHKatherine Anne Heinzman
Katherine Anne Heinzman
KGKadir Gultekin
Kadir Gultekin
CCCarlos E. Cardenas
Carlos E. Cardenas
Background/Objectives: Medical research institutions are increasingly leveraging artificial intelligence (AI) to enhance the processing and analysis of medical imaging data. However, scaling AI-driven medical image analysis often requires specialized expertise and infrastructure that individual labs may lack. A centralized solution is to establish a core facility—a shared institutional resource—dedicated to Automated Medical Image Processing and Analysis (AMIPA). Methods: This technical note offers a practical roadmap for institutions to create an AI-based core facility for AMIPA, drawing on our experience in building such a resource. Results: We outline the key components for replicating a successful AMIPA core facility, including high-performance computing resources, robust AI software pipelines, data management strategies, and dedicated support personnel. Emphasis is placed on workflow automation and reproducibility, ensuring researchers can efficiently and consistently process large imaging datasets. Conclusions: By following this roadmap, institutions can accelerate AI adoption in imaging workflows and foster a shared resource that enhances the quality and productivity of medical imaging research.

2 October 2026 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
KGKadir Gultekin
Kadir Gultekin
JBJennifer Bartels
Jennifer Bartels
CCCarlos E. Cardenas
Carlos E. Cardenas
YKYogesh Kumar
Yogesh Kumar
GGGrayson R. Gimblet
Grayson R. Gimblet
JMJonathan E. McConathy
Jonathan E. McConathy
Purpose: Cell tracking with zirconium-89 PET has the potential for widespread clinical and research applications, including imaging infection and inflammation and tracking cell-based therapies. This prospective first-in-human clinical trial assessed the dosimetry and safety profile of [ 89 Zr]Zr-oxine-labeled autologous leukocytes in healthy female participants. Methods: Four healthy adult female participants (ages 37–53) received 10.9 ± 2.9 MBq of [ 89 Zr]Zr-oxine-labeled autologous leukocytes and underwent whole-body PET/CT imaging at five time points (0, 4, 24, 48, and 72 h). Regions of interest were automatically segmented on CT using a machine learning-based approach and manually refined. Time-integrated activity coefficients were calculated using Simpson’s rule, with physical decay assumed beyond the final time point. Mean absorbed-dose and effective-dose coefficients were estimated using OLINDA 2.1. Results: Administration was well-tolerated among all participants. The highest mean absorbed-dose coefficients (mGy/MBq) with standard deviation were observed in the spleen (3.52 ± 1.38), liver (2.1 ± 0.45), adrenals (1.62 ± 0.24), uterus (1.48 ± 0.98), and kidneys (1.36 ± 0.12). The mean effective-dose coefficient was 0.92 ± 0.06 mSv/MBq, numerically lower than the predicted value of 1.14 mSv/MBq based on the distribution of [ 111 In]In-oxine-labeled leukocytes in adult females ( P = 0.006, one-sample t-test). The use of [ 89 Zr]Zr-oxine-labeled leukocytes enabled the visualization of leukocyte distribution and temporal dynamics. Conclusion: This study demonstrates the safety and favorable dosimetry of [ 89 Zr]Zr-oxine-labeled leukocytes in healthy humans. These results support the further use of this approach for imaging autologous leukocytes using PET in a range of clinical and research settings. Trial registration: ClinicalTrials.gov NCT03807973. Registered January 16, 2019.